Impact on health-related quality of life of the addition of bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS phase III trial.

Affiliation auteurs!!!! Error affiliation !!!!
TitreImpact on health-related quality of life of the addition of bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS phase III trial.
Type de publicationJournal Article
Year of Publication2018
AuteursWesteel V, Eberst G, Anota A, Scherpereel A, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Herve L, Riviere F, Monnet I, Gounant V, Janicot H, Gervais R, Locher C, Morin F, Zalcman G
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume36
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2018.36.15_suppl.8505